| Bid | 1.71 |
| Market Cap | 165.34M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.39 |
| PE Ratio (ttm) | -0.72 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.72 |
| Volume | 65,594 |
| Avg. Volume (20D) | 892,431 |
| Open | 1.79 |
| Previous Close | 1.71 |
| Day's Range | 1.70 - 1.82 |
| 52-Week Range | 1.68 - 6.04 |
| Beta | undefined |
About ADCT
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second...
Analyst Forecast
According to 5 analyst ratings, the average rating for ADCT stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 367.84% from the latest price.
Next Earnings Release
Analysts project revenue of $19.52M, reflecting a 16.26% YoY growth and earnings per share of -0.38, making a -60.82% decrease YoY.
1 month ago · seekingalpha.com
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCLInitial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, u...
